Twist Bioscience Corporation Cash and Restricted Cash
Twist Bioscience Corporation (TWST) had Cash and Restricted Cash of $119.57 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-03
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $119.57M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $124.85M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $150.99M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $185.43M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $119.57M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $124.85M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $150.99M 10-Q/A · filed 2026-02-26 | |
| 2025-09-30 | $185.43M 10-Q · filed 2026-08-03 | |
| 2025-06-30 | $203.91M 10-Q · filed 2026-08-03 | |
| 2025-03-31 | $212.95M 10-Q · filed 2026-05-04 | |
| 2024-12-31 | $224.06M 10-Q/A · filed 2026-02-26 | |
| 2024-09-30 | $229.13M 10-Q · filed 2026-08-03 | |
| 2024-06-30 | $242.04M 10-Q · filed 2025-08-04 | |
| 2024-03-31 | $246.22M 10-Q · filed 2025-05-05 | |
| 2023-12-31 | $269.12M 10-Q · filed 2025-02-03 | |
| 2023-09-30 | $289.28M 10-K · filed 2025-11-17 | |
| 2023-06-30 | $311.84M 10-Q · filed 2024-08-02 | |
| 2023-03-31 | $317.56M 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $319.09M 10-Q · filed 2024-02-02 | |
| 2022-09-30 | $380.26M 10-K · filed 2025-11-17 | |
| 2022-06-30 | $377.82M 10-Q · filed 2023-08-07 | |
| 2022-03-31 | $409.20M 10-Q · filed 2023-05-08 | |
| 2021-12-31 | $193.20M 10-Q · filed 2023-02-07 | |
| 2021-09-30 | $467.36M 10-K · filed 2024-11-18 | |
| 2021-06-30 | $476.81M 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $400.86M 10-Q · filed 2022-05-06 | |
| 2020-12-31 | $350.32M 10-Q · filed 2022-02-09 | |
| 2020-09-30 | $94.25M 10-K · filed 2023-11-21 | |
| 2020-06-30 | $208.52M 10-Q · filed 2021-08-09 | |
| 2020-03-31 | $185.06M 10-Q · filed 2021-05-07 | |
| 2019-12-31 | $26.95M 10-Q · filed 2021-02-09 | |
| 2019-09-30 | $47.40M 10-K/A · filed 2023-06-05 | |
| 2019-06-30 | $68.98M 10-Q · filed 2020-08-12 | |
| 2019-03-31 | $29.49M 10-Q · filed 2020-05-13 | |
| 2018-12-31 | $67.09M 10-Q · filed 2020-02-10 | |
| 2018-09-30 | $81.54M 10-K · filed 2021-11-23 | |
| 2018-06-30 | $91.10M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $78.63M 10-Q · filed 2019-05-02 | |
| 2017-12-31 | $26.29M 10-Q · filed 2019-02-11 | |
| 2017-09-30 | $31.57M 10-K · filed 2020-11-27 | $31.43M 10-Q · filed 2019-02-11 |
| 2016-09-30 | $29.06M 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |